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Background: There is conflicting evidence on the impact of biologic treatment on the
rate of complications and surgeries in Crohn’s disease (CD). We aimed to assess real-
world consequences of biologic treatment of CD.
Methods: All adult patients with CD treated with infliximab and adalimumab in the
years 2012–2014 were identified from the database of the National Health Fund in
Poland. Mixed models were used to assess the impact of biologics on medical resource
utilization by comparing the periods before and after the first use of biologics (pre-index
vs. post-index). The additional analyses including quintile of total exposure to biologic
treatment were performed.
Results: Data on 1393 patients (age, 31.9 years; males, 52.6%) were analyzed over a
median of 1064 days (range: 71, 1148). During the post-index period, patients received
from one to four treatments with biologic agents (maximum allowed period of 12 months
per treatment). We observed a reduction in the rates of surgeries (by 27%, p = 0.001),
hospitalizations for CD excluding surgical procedures (by 45%, p < 0.001), as well as
consumption of antibiotics (by 31%, p < 0.001) and steroids (by 35%, p < 0.001) in the
post-index compared with the pre-index period. The reduction in the rate of surgeries,
hospitalizations for CD, and steroid intake increased with the increase of exposure to
biologic agents.
Conclusion: Biologic treatment changed the management patterns by lowering the
rate of surgeries and other healthcare resources related to complications or worsening
of CD. The reduction in the resource utilization was dependent on the level of exposure
to treatment, suggesting that limitation of the treatment period itself may be inadequate.
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INTRODUCTION
Crohn’s disease (CD) is a chronic, relapsing inflammatory disease affecting the gastrointestinal
tract, with intestinal and extraintestinal complications and other immune disorders (Baumgart
and Sandborn, 2012). The management is medical and surgical, but treatment patterns have
changed radically over the past years, with an increase in the use of immunomodulatory drugs and
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introduction of biologic therapy. Historically, up to 80% of
CD patients had surgery at some stage (Cummings et al.,
2008; Burisch et al., 2013). The biologic treatment is effective
in achieving clinical response and remission in moderate-to-
severe CD, but its impact on the rate of complications and, in
particular, necessity of surgery is not clear (Sokol et al., 2014;
Annese et al., 2016). A recent systematic review of clinical trials
indicated that biologic treatment of CD reduces the rate of
surgeries and hospitalizations compared with placebo (Mao et al.,
2017). The design of the included trials (e.g., continuation of
treatment despite minimal or no response) and post hoc feature of
individual trial’s result limit the generalizability of the conclusion.
On the other hand, the real-world data are heterogeneous and
conflicting (Sokol et al., 2014; Annese et al., 2016). Some studies
demonstrated that despite increasing intake of biologics, the rate
of hospitalizations and surgeries has reminded unchanged or
increased (Bewtra et al., 2007; Nguyen et al., 2007; Lazarev et al.,
2010; Sokol et al., 2014; Jeuring et al., 2017). A meta-analysis
of population-based studies indicated the reduction of risk for
surgery in CD with time (Frolkis et al., 2013), but heterogeneity
and other limitations (e.g., studies not designed to identify the
specific cause) did not allow to assign a causal relationship of the
trend with biologic treatment (Sokol et al., 2014). For example,
the trend might have as well been explained by increase in the use
of immunomodulators (Vester-Andersen et al., 2014) or by other
factors (Jeuring et al., 2017).
It has been shown that the frequency of hospitalizations and
surgical procedures among CD patients varies between countries
(Odes et al., 2006; Vegh et al., 2015). Hence, the impact of biologic
treatment on those events may also depend on the setting.
In some countries, including Poland and United Kingdom,
authorities limit the duration of biologic treatment to a maximum
of 12 months. To our knowledge, our study is the first analysis of
such a treatment scheme.
In the absence of reliable information on the consequences
of biologic treatment of CD, there is limited ability to properly
prioritize treatment, valuate new biologics, or determine their
optimal sequence using a cost-utilitarian approach. As a
result, most economic evaluations omitted or incorporated own
assumptions regarding the impact of biologics on treatment
patterns and rate of surgeries (Huoponen and Blom, 2015).
Therefore, we decided to conduct a study to assess real-world
consequences of biologic treatment of CD in all adult patients
with CD treated in Poland in the years from 2012 to 2014.
MATERIALS AND METHODS
Study Design and Patients
This was a retrospective analysis of medical resource utilization
among patients with CD treated with infliximab or adalimumab
in the years from 2012 to 2014 in Poland. The cohort was
identified from the database of the National Health Fund [in
Polish, Narodowy Fundusz Zdrowia (NFZ)], a public payer for
all medical services in Poland.
In Poland, biologic treatment was provided through a
program called a Drug Program (i.e., a set of in- and out-patient
services) that included separate procedures for acquisition of
biologic agents, their administration or self-administration, and
diagnostics during biologic treatment. The inclusion criteria
for the program among adult patients were: (i) severe, active
CD (activity index > 300) with lack of response to treatment,
contraindications, or intolerance to treatment with steroids,
immunomodulatory drugs, or other tumor necrosis factor-α
inhibitor; or (ii) perianal fistulas which do not heal despite
treatment with antibiotics and surgical treatment in combination
with immunomodulatory therapy. The exclusion criteria were as
follows: hypersensitivity; severe infections; moderate or severe
heart failure; unstable angina; chronic respiratory, renal, or liver
failure; demyelinating syndrome-like symptoms; alcoholism;
active progressive liver disease; pregnancy or breastfeeding; the
diagnosis of precancerous state and malignant tumors during
the previous 5 years; and complications requiring a change of
treatment (e.g., surgeries with the exception of procedures for
closing fistulas). The induction treatment (around 100 days) was
administered to all patients (with or without response). However,
the maintenance treatment was available for the responders only.
Overall, the biologic treatment was continuously administered
for a period of no longer than 12 months. However, eligible
patients could re-enter treatment, that is, start induction phase
after 16 and 8 weeks since the last dose of infliximab and
adalimumab, respectively.
The eligibility criteria for the study were at least one
administration of biologics in the program for CD and age of
18 years or older during the first biologic treatment. Patients
using infliximab or adalimumab in other programs and patients
below 17 years of age at the first administration of biologics
were excluded owing to different criteria for continuation of
treatment.
Data Source and Management
We used part of the database that initially contained information
for all patients with inflammatory bowel disease in Poland
and was created for the National Institute of Public Health –
National Institute of Hygiene (Holko et al., 2018). The database
contained information on date of birth, sex, province of
residence (province), all in-patient and out-patient services
and all medications, diet supplements, nutritional products, or
medical devices on prescription. In this study, data on eligible
patients were extracted. All medical resources used between the
first and the last resource utilization in the years from 2012 to
2014 for each eligible patient were analyzed.
To verify the main hypothesis regarding the difference
in resource utilization according to the exposure to biologic
treatment, the observation period for each patient was divided
according to an index date of the first administration of a biologic
drug [before the first administration (pre-index period) and after
the first administration of a biologic drug (post-index period)].
All medical procedures with the directional ICD-10 (the 10th
revision of the International Statistical Classification of Diseases
and Related Health Problems) code of CD or related intestinal
or extraintestinal complications were considered as being
directly related to CD. The medium, large, or complex surgical
procedures [identified using the “diagnosis-related group” (DRG)
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codes] directly related to CD (as described above) and performed
in any department of a medical center were considered as
surgeries for CD (Supplementary Table S1). Hospitalization was
defined as a planned or an unplanned hospital stay (including an
emergency department) for more than 1 day.
The number of packs was used as a unit of antibiotics and
systemic glucocorticoid intake.
The rates of surgeries for CD, hospitalizations for
CD (excluding hospitalizations for surgical procedures),
consumption of steroids, and consumption of antibiotics were
the main endpoints of the study because they directly related
to complications or worsening of CD. The rate of all resources
(i.e., hospitalizations, ambulatory specialist consultations, or
ambulatory services) irrespectively of the relation to CD and
services related to administration of biologics and diagnostic
procedures during biologic treatment were assessed to validate
the resource selection process and to validate the conclusions
against any confounders that were not directly observed.
The principal and secondary diagnosis ICD-10 codes
established for each patient over the first 6 months of the study
were used to calculate the Charlson comorbidity index score
using the coding algorithm described by Quan et al. (2005).
The Classification of Territorial Units for Statistics was used for
grouping patients by the geographical regions of Poland.
Statistical Analysis
All study outcomes and patients’ characteristics were analyzed
descriptively and presented as a mean with SD or median
with interquartile range (IQR) for continuous variables and as
frequencies for categorical variables.
The generalized linear mixed models with Poisson or negative
binominal (when overdispersion was present) distribution, log
link, robust errors, period duration as a quantification of
exposure, and random intercepts by patient were used to
assess medical resource utilization during the study periods
(pre- vs. post-index). The secondary analysis included the
interaction of a variable describing study periods and that
describing the quintile of total exposure to biologic treatment
during the post-index period. All models included age, sex,
comorbidity score, and region of Poland to control for possible
confounders. The models with “exposure” variable allowed us to
determine the incidence rate ratio (IRR) for each predictor while
considering the differences in period duration. Model selection
and assessment were based on the characteristics of dependent
variable, residual distribution, random effect distribution, and
Akaike information criterion. Average adjusted predictions were
presented as adjusted means with confidence intervals (CIs)
calculated using the delta method. Unless stated otherwise, the
average adjusted marginal effects were indicated as adjusted
difference in annualized rates.
Missing data were excluded from the descriptive analysis of an
outcome, but patients with missing observations were included in
mixed models. The Bonferroni correction for multiple hypothesis
testing was incorporated. To ensure self-explanatory attribute of
the results, the p values and CIs were adjusted with the correction,
that is, the adjusted p values were presented as p values and CIs
adjusted for multiplicity were presented as 95% CIs. The adjusted
p value of less than 0.05 (nominal p value of less than 0.001) was
considered statistically significant.
The study was reported in adherence with the Strengthening
the Reporting of Observational Studies in Epidemiology
Statement (von Elm et al., 2008).
Data preparation and statistical analyses were done using
Access 2016 (Microsoft Co., Redmond, WA, United States) and
STATA 14.2 (StataCorp, College Station, TX, United States).
Figures were prepared using OriginPro 2017 (OriginLab,
Northampton, MA, United States).
Ethics Statement
This article does not contain any studies with animals or humans
performed by any of the authors (retrospective database analysis).
RESULTS
Characteristics of Patients
A total of 1613 patients were treated in the program for CD in the
years from 2012 to 2014. Fourteen patients were excluded because
of treatment with infliximab or adalimumab in other programs
(psoriasis, ankylosing spondylitis, or ulcerative colitis) and 206
were excluded because of age.
The study included 626 patients treated with infliximab, 587
patients treated with adalimumab, and 180 patients treated with
both biologics. A total of 1050, 285, 56, and 2 patients received
one, two, three, and four biologic treatments, respectively, during
follow-up. The mean age at the first administration of biologics
was 31.9 years (SD 11.1; range: 17.0, 79.4), and 52.6% of the
patients were male. Most of the patients (94.4%) had no life-
threatening comorbidities (comorbidity score of 0), and 44.7%
were from the eastern or central region of Poland. The rates
of immunomodulatory drug and steroid use did not differ
TABLE 1 | Characteristics of patients at the start of the first biologic treatment.
Value
Number of patients 1393
Age in years at start of treatment, mean (SD) 31.9 (11.1)
Women, n (%) 661 (47.5)
Comorbidity score
0, n (%) 1315 (94.4)
1+, n (%) 78 (5.6)
Region of Poland
Eastern or central, n (%) 623 (44.7)
North or north-western, n (%) 409 (29.4)
South or south-western, n (%) 361 (25.9)
Biologic treatment
Number of patients (%) with maintenance treatmenta 1035 (74.3)
Total exposure in days, median (IQR) 314 (134, 365)
Rate of other medication use during biologic treatment
Immunomodulators, n (%) 774 (55.6)
Steroids, n (%) 437 (31.4)
aPatients continuing induction treatment at the end of the study period were
excluded.
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significantly between patients treated with adalimumab and
those treated with infliximab at the index date and between
patients during subsequent biologic treatments (Table 1 and
Supplementary Table S2).
The median observation period (pre- and post-index) was
1064 days (IQR: 1026, 1084), with a median post-index period
of 644 days (IQR: 294, 994) and a median cumulative duration
of biologic treatment of 314 days (IQR: 134, 365). Overall, the
study included 1512.2 patient-years during the pre-index period
and 2382.3 patient-years during the post-index period.
Resource Utilization
Among the 678 patients, there were 1045 surgeries for CD,
including 482 surgeries (346 patients) before, 150 surgeries (140
patients) during, and 413 surgeries (308 patients) after biologic
treatment. Of 150 surgeries, 40.7% most probably resulted in
discontinuation of biologic treatment, that is, they occurred
during the estimated treatment period, between the last and
the next expected administration of biologics according to the
treatment schedule. The average rate of surgery for CD was
reduced with biologic treatment by 27% in comparison to the
pre-index period (95% CIs: 8%, 42%, i.e., −0.08 events per year,
p = 0.001; Supplementary Table S3).
The rate of hospitalizations for CD was reduced by −0.73
events per year (p < 0.001). A significant effect of biologic
treatment on the intake of steroids (−1.52 packs per year,
p < 0.001) and antibiotics (−0.56, p < 0.001) was observed.
The rates of all hospitalizations (adjusted difference of −0.40
events per year, p < 0.001) and all ambulatory consultations with
a specialist (−2.93, p < 0.001) were significantly reduced, but the
rate of all ambulatory services did not differ between the pre-
and post-index periods (−0.02 events per year; 95% CIs: −0.24,
0.20). The reduction in the rate of all specialist consultation
was partially compensated with additional services related to
administration of biologics or performing diagnostic procedures
during biologic treatment (Table 2).
The reduction in the rates of surgeries, other hospitalizations
for CD, and steroid intake increased with higher exposure to
biologic agents. The trend was not observed for antibiotic intake
(Figure 1).
DISCUSSION
The conflicting evidences on the impact of biologic treatment
on the rate of complications and necessity of surgery in CD
provided the rationale for this study. All adult patients with CD
treated with infliximab and adalimumab in the years 2012–2014
in Poland were included in the study. Biologic treatment reduced
the rates of surgeries, hospitalizations for other causes related
to CD or its complications, and consumption of antibiotics and
steroids in real-world setting.
The strengths of our study include the size and heterogeneity
of participants, which was obtained by a non-selective inclusion
of all patients treated with biologics in Poland. However,
the source of the data constitutes an important limitation of
the study. The data were obtained from an administrative
database of medical resources and are susceptible to errors
made during the reporting of the resources by providers (e.g.,
inaccurate ICD-10 codes). Moreover, the detailed information
on clinical characteristics of patients’ disease was not available.
However, only patients meeting the specific inclusion criteria
(i.e., active CD – progression or relapse – during steroid or
immunosuppressive therapy) were allowed to start biologic
treatment in Poland and it is likely that all those patients from
Poland were included in this study.
Although justified by the changes in Polish healthcare system
in 2012 and incompleteness of data from 2015 at the time of data
extraction, the duration of follow-up period limited to the years
2012–2014 is another drawback. The first biologic treatment
in the study period was not necessarily the first ever biologic
treatment in some percentage of the patients (the treatment
was formally introduced in Poland in 2007). However, 52%
of the patients were followed for at least 6 months prior to
the first biologic treatment in this study. The duration of the
follow-up period limited to 3 years was sufficient to analyze
the impact of biologic treatment on the rate of the selected
events, because the duration of biologic treatment was limited to
12 months in Poland and all the resources analyzed (including
some types of surgeries) were allowed to be used during biologic
treatment. Moreover, the relationship between biologic treatment
and the reduction in the rate of surgeries and other resources was
confirmed by assessing the association between that reduction
and the level of exposure to biologic treatment.
Another limitation includes the assumption of the analyses,
that is, the consumption of steroids and antibiotics was assumed
to occur immediately after supply and all missing observations
were treated as random. The comparison was affected by a
potentially different course of the disease (e.g., diagnosis of
steroid-refractory or steroid-dependent disease around the index
date). Patients served as their own controls, which means that the
possibility of a patient improving spontaneously at the start of
biologic treatment as a result of the so-called “regression toward
the mean” cannot be excluded. However, similar outcomes
among all patients during the pre-index period and patients
exposed to biologics for 100 days or less during the post-index
period (most likely non-responders) suggest that the effect of this
phenomenon is minimal.
Our study included patients with severe CD only, while most
participants in clinical trials had moderate to severe CD. In
addition to a different definition of the outcome and different
settings, this explains the difference in the rate of surgeries
between our study (0.24–0.35 per year) and clinical trials (0.06–
0.13; Mao et al., 2017).
Several sensitivity analyses were conducted to address the
limitations of our study (data not shown). The exclusion of
patients with the pre-index period shorter than 6 months did not
affect most of the conclusions. The assessment of consumption
of steroids with daily dose as a unit instead of a pack indicated
higher impact of biologic treatment (e.g., reduction of 62%
vs. pre-index), but the models less accurately fitted the data
owing to the semi-continuous character of dependent variable
and required more complex methods. Another analysis showed
similar outcomes among patients on combination therapy (i.e.,
Frontiers in Pharmacology | www.frontiersin.org 4 June 2018 | Volume 9 | Article 621
fphar-09-00621 June 8, 2018 Time: 16:18 # 5
Holko et al. Biologics Impact – Surgery for CD
administration of biologic agent with immunomodulatory drug
for >50% of the period of biologic treatment) and those on
monotherapy.
The study results are in line with the findings from some
cohort studies and randomized clinical trials. In their meta-
analysis of randomized clinical trials, Mao et al. (2017) showed
that the odds for CD-related hospitalization and surgery are
reduced with biologic treatment compared with placebo by 53%
and 74%, respectively. Similarly, a meta-analysis of observational
studies with various design (pre-treatment vs. post-treatment,
responders vs. non-responders, etc.) indicated a reduction of 72%
and 68% in the odds for hospitalization and surgery, respectively,
with infliximab monotherapy (Costa et al., 2013), but some
individual studies indicated an increase in the rate of surgeries
with biologic treatment (Park et al., 2014). On the contrary,
Lazarev et al. (2010), in a single-center study, showed no change
in rate of surgery with increasing use of biologic treatment, and
Jeuring et al. (2017) reported no association between reduction in
the rate of surgeries and biologic treatment. Both studies focused
on the total cohort of CD patients and did not assess management
patterns at the patient level.
The level of reduction in the rate of surgeries and
hospitalizations was lower in our study (27% and 45%,
respectively) than that reported by Costa et al. (2013; 68%
and 72%, respectively) or Mao et al. (2017; 74% and 53%,
respectively). The observed differences may be explained by
different settings, because it was shown that the frequency of
hospitalizations and surgical procedures among patients with CD
varies significantly between countries (Odes et al., 2006; Vegh
et al., 2015). However, the observed correlation between the
reduction in the resource utilization and the level of exposure
to biologic agents suggested that the difference in the level of
reduction in the rate of surgeries and hospitalizations between
our study and others is mainly caused by the limitation of the
treatment period to 12 months in Poland. The higher reduction of
resources utilization in studies without this limitation suggested
that it may be inadequate to achieve long-term clinical benefit
from biologic treatment. On the other hand, it may suggest that
biologic treatment prevents complications and worsening of CD
in clinical practice, but mainly during treatment. Since January
2017, the biosimilar infliximab can be used in the treatment of
CD for a longer period in Poland (up to 24 months). Possibly,
future research regarding longer treatment period will be able
to confirm these observations (i.e., the level in the reduction of
surgeries depending on the allowed treatment period and/or the
presence of the reduction during treatment only).
TABLE 2 | The annualized rates of medical services and medication intake before and after the first administration of biologics (pre- and post-index, respectively).
Estimate Pre-index Post-index
Follow-up (patient-years) Totals 1512.2 2382.3
Surgeries for CDa Unadjusted mean (totals) 0.35 (482) 0.24 (563)
Adjusted mean (95% CIs)b 0.32 (0.27, 0.38) 0.24 (0.20, 0.27)
IRR (95% CIs) – 0.73 (0.58, 0.92)∗
Hospitalizations for CDa,c Unadjusted mean (totals) 1.53 (2306) 0.91 (2158)
Adjusted mean (95% CIs)b 1.61 (1.43, 1.78) 0.88 (0.78, 0.98)
IRR (95% CIs) – 0.55 (0.47, 0.63)∗∗
Steroids (packs) Unadjusted mean (totals) 4.39 (6635) 2.71 (6443)
Adjusted mean (95% CIs)b 4.31 (3.60, 5.02) 2.79 (2.36, 3.23)
IRR (95% CIs) – 0.65 (0.52, 0.82)∗∗
Antibiotics (packs) Unadjusted mean (totals) 1.75 (2639) 1.30 (3107)
Adjusted mean (95% CIs) b 1.81 (1.55, 2.08) 1.25 (1.08, 1.43)
IRR (95% CIs) – 0.69 (0.58, 0.82)∗∗
Services related to biologicsd Unadjusted mean (totals) 0 (0) 5.60 (13,291)
All hospitalizationse Unadjusted mean (totals) 1.87 (2827) 1.51 (3587)
Adjusted mean (95% CIs)b 1.90 (1.73, 2.08) 1.50 (1.36, 1.64)
IRR (95% CIs) – 0.79 (0.69, 0.89)∗∗
All ambulatory consultations with a specialistf Unadjusted mean (totals) 6.06 (9160) 4.00 (9519)
Adjusted mean (95% CIs)b 6.68 (6.04, 7.31) 3.75 (3.42, 4.09)
IRR (95% CIs) – 0.56 (0.51, 0.62)∗∗
All ambulatory servicesg Unadjusted mean (totals) 0.56 (842) 0.47 (1110)
Adjusted mean (95% CIs)b 0.53 (0.28, 0.78) 0.51 (0.31, 0.71)
IRR (95% CIs) – 0.96 (0.63, 1.45)
CD, Crohn’s disease, IRR, incidence rate ratio. ∗p = 0.001; ∗∗p < 0.001. aSee Supplementary Table S1 for details. bAverage adjusted predictions of generalized linear
mixed models with age, sex, region, comorbidity score, and binary variable indicating pre-index or post-index periods (Supplementary Table S3). cSurgeries for CD
and hospitalizations related to administration of biologics or performing diagnostics during biologic treatment were not included. dHospitalization, 1-day hospitalization,
or outpatient visit indicated as for biologic administration or performing diagnostic procedures during biologic treatment. eSurgeries for CD, hospitalizations for CD,
hospitalizations related to biologic treatment, and hospitalizations not related to CD. fAll ambulatory consultations, i.e., consultations with simple diagnostic procedures
(e.g., X-ray, ultrasound, urine, or blood tests), consultations solely for prescriptions, etc. gMedical interventions performed as part of the “Outpatient Specialist Care” (in
Polish,“Ambulatoryjna Opieka Specjalistyczna”; general examples: introduction of a catheter, biopsies, incision of abscess, and tooth extraction) were included.
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FIGURE 1 | Adjusted and unadjusted difference between the post-index and pre-index periods in annualized rates of surgery for Crohn’s disease (A), other
hospitalizations for Crohn’s disease (B), and consumption of steroids (C) and antibiotics (D) by the quintile of total exposure to biologic agents. Error bars indicate
95% confidence intervals. ∗0.05 > p ≤ 0.01; ∗∗0.01 > p ≤ 0.001; and ∗∗∗p < 0.001.
Limitation of the treatment period to 12 months in Poland,
adverse events and loss of response preventing continuous long-
term treatment, and different designs were presumably the
reasons for the discrepancies between our study and population
studies. The change of treatment patterns at the patient level
cannot translate to the effect that can be observed in the whole
CD population, especially if the rate of biologic treatment is
low. The study showed that around half of the patients received
biologic treatment in combination with immunomodulatory
drugs and around half of them discontinued treatment before
the end of the maximum allowed period of 12 months.
Discontinuation of treatment may occur for several reasons, such
as patient preference, achievement of stable remission, lack or
loss of response, adverse events, or pregnancy. Even though
the cause could not be determined, the high discontinuation
rate indicates that there is an unmet treatment need in patients
with CD. High relapse rates after discontinuation of treatment
in this study (re-treatment in 26–40% of patients after a
year) and in other studies identified in a systematic review
by Gisbert et al. (2015) may indicate that biologic treatment
requires continuous administration or setting long-term clinical
goals.
The results of this study are clinically and economically
relevant because the outcomes are considered to be markers
of disease severity and contribute to the considerable share of
healthcare costs of the disease. Furthermore, the results can be
used to inform economic models created to assess the cost-
effectiveness of biologics or to assess optimal treatment sequence.
Finally, with the largest cohort of adult patients using biologic
treatment to date (Costa et al., 2013; Annese et al., 2016) and a
non-selective process of patient inclusion, the results of this study
provide a sound argument in an ongoing debate on real-world
outcomes of biologic treatment and changes in management
patterns induced by the treatment.
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